Ehrlich, P. Ueber den jetzigen Stand der Karzinomforschung. Ned. Tijdschr. Genees. 53, 273–290 (1908).

Thomas, L. Cellular and Humoral Aspects of the Hypersenstive States (ed. Lawrence, H.) 529–532 (Hoeber-Harper, 1959).

Shankaran, V. et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107–1111 (2001).

Article  CAS  PubMed  Google Scholar 

Zehn, D. & Bevan, M. J. T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity 25, 261–270 (2006).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brunet, J. F. et al. A new member of the immunoglobulin superfamily—CTLA-4. Nature 328, 267–270 (1987).

Article  CAS  PubMed  Google Scholar 

Krummel, M. F. & Allison, J. P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459–465 (1995).

Article  CAS  PubMed  Google Scholar 

Wing, K. et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322, 271–275 (2008).

Article  CAS  PubMed  Google Scholar 

Zappasodi, R. et al. CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours. Nature 591, 652–658 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ishida, Y., Agata, Y., Shibahara, K. & Honjo, T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11, 3887–3895 (1992).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dong, H., Zhu, G., Tamada, K. & Chen, L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5, 1365–1369 (1999).

Article  CAS  PubMed  Google Scholar 

Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027–1034 (2000).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).

Article  PubMed  PubMed Central  Google Scholar 

Woo, S. R. et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 72, 917–927 (2012).

Article  CAS  PubMed  Google Scholar 

Anderson, A. C., Joller, N. & Kuchroo, V. K. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44, 989–1004 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24–34 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muul, L. M., Spiess, P. J., Director, E. P. & Rosenberg, S. A. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 138, 989–995 (1987).

Article  CAS  PubMed  Google Scholar 

Mullard, A. FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers. Nat. Rev. Drug Discov. 23, 238 (2024).

Article  CAS  PubMed  Google Scholar 

Robbins, P. F. et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21, 1019–1027 (2015).

Article  CAS  PubMed  Google Scholar 

Imai, C. et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18, 676–684 (2004).

Article  CAS  PubMed  Google Scholar 

Krause, A. et al. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med. 188, 619–626 (1998).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baker, D. J., Arany, Z., Baur, J. A., Epstein, J. A., & June, C. H. CAR T therapy beyond cancer: the evolution of a living drug. Nature 619, 707–715 (2023).

Article  CAS  PubMed  Google Scholar 

June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449–459 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388, 1002–1014 (2023).

Article  CAS  PubMed  Google Scholar 

Zebley, C. C. et al. CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia. Cell Rep. 37, 110079 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359–371 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Albelda, S. M. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat. Rev. Clin. Oncol. 21, 47–66 (2024).

Article  PubMed  Google Scholar 

Prinzing, B. et al. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci. Transl. Med. 13, eabh0272 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bell, M. et al. Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK/STAT signalling. Nat. Biomed. Eng. 8, 380–396 (2023).

Wei, J. et al. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature 576, 471–476 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fix, S. M., Jazaeri, A. A. & Hwu, P. Applications of CRISPR genome editing to advance the next generation of adoptive cell therapies for cancer. Cancer Discov. 11, 560–574 (2021).

Article  CAS  PubMed  PubMed Central